Multiple Myeloma Bispecifics Vie For Leadership Based On Safety, Combinability
Janssen Has First Combo Data, With Its Own Darzalex
Executive Summary
Updates at ASH for bispecifics targeting BCMA, GPRC5D and FcRH5 from Regeneron, Janssen, Pfizer, Roche, AbbVie and Harpoon show monotherapy efficacy, initial combination data and potential safety differentiation.
You may also be interested in...
Ichnos CEO On The ‘ASH Of Bispecifics’, Progress With Trispecific
Ichnos’ CEO Dr Cyril Konto highlights promising early data presented at ASH for the firm’s trispecific antibody in multiple myeloma versus teclistamab and alnuctamab. He also outlines why the US-based spin out of Glenmark isn’t considering the special purpose acquisition company alternative to the conventional IPO.
Multiple GPRC5D Agents For Myeloma Raise Questions On Positioning
J&J’s talquetamab is in the lead among bispecific antibodies, while Roche and BMS are not far behind. Presentations at ASH sparked discussion on how to position them in treatment.
Keeping Track: RSV Vaccine Race Heats Up Between Pfizer And GSK; Another J&J Bispecific For Myeloma
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.